• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

Valrubicin Inhibitor

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5758492

Valrubicin (AD 32) inhibits TPA- and PDBu-induced PKC activation (IC50s: 0.85 and 1.25uM) and has antitumor and anti-inflammatory activity. More details

Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
Valrubicin, Inhibitor
Full Product Name
Valrubicin
Product Synonym Names
AD-32
Form/Format
Solid. Powder
Purity/Purification
98.00%
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
Molecular Weight
723.64
Solubility
DMSO: 125mg/mL (172.74mM)
Water: Insoluble
(<1mg/ml refers to the product slightly soluble or insoluble)
Formula
C34H32F3NO13
SMILES
CCCCC(OCC([C@]1(O)CC2=C(C(O)=C3C(C4=C(C(C3=C2O)=O)C=CC=C4OC)=O)[C@@H](O[C@]5C[C@](NC(C(F)(F)F)=O)[C@](O)[C@](C)O5)C1)=O)=O
CAS Number
56124-62-0
Cell Research
UMSCC5 cells exposed to Valrubicin (2uM for 3 h), a single dose of radiation (400 cGy), or the combined treatment,are cultured for a further 12, 24, or 48 hours. At these times, the cells are collected by trypsinization (0.25%), washed in PBS, and fixed at 5 x 10^6 cells/mL with 95% ethanol. Cells are incubated with ribonuclease (50 ug; 70-90 Kunitzunits/mg for 30 min), and the resulting pellet resuspended in and incubated with propidium iodide (0.05mg/mL for 10 min). The DNA content of the samples is determined by flow cytometry according to standard technique [2].

Product Categories/Family for Valrubicin, inhibitor

Product References and Citations for Valrubicin, inhibitor

Chuang LF, et al. Activation of human leukemia protein kinase C by tumor promoters and its inhibition by N-trifluoroacetyladriamycin-14-valerate (AD 32). Biochem Pharmacol. 1992 Feb 18;43(4):865-72.
Chuang LF, et al. Activation of human leukemia protein kinase C by tumor promoters and its inhibition by N-trifluoroacetyladriamycin-14-valerate (AD 32). Biochem Pharmacol. 1992 Feb 18;43(4):865-72.
Wani MK, et al. Rationale for intralesional valrubicin in chemoradiation of squamous cell carcinoma of the head and neck. Laryngoscope. 2000 Dec;110(12):2026-32.
Wani MK, et al. Rationale for intralesional valrubicin in chemoradiation of squamous cell carcinoma of the head and neck. Laryngoscope. 2000 Dec;110(12):2026-32.
Hauge E, et al. Topical valrubicin application reduces skin inflammation in murine models. Br J Dermatol. 2012 Aug;167(2):288-95.
Hauge E, et al. Topical valrubicin application reduces skin inflammation in murine models. Br J Dermatol. 2012 Aug;167(2):288-95.

Other Notes

Small volumes of Valrubicin, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Valrubicin purchase

MBS5758492 is an inhibitor targeting Valrubicin.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000